Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeletal dynamics in platelets
Begoña Hurtado, … , Pablo García de Frutos, Marcos Malumbres
Begoña Hurtado, … , Pablo García de Frutos, Marcos Malumbres
Published December 3, 2018; First published September 25, 2018
Citation Information: J Clin Invest. 2018;128(12):5351-5367. https://doi.org/10.1172/JCI121876.
View: Text | PDF
Categories: Research Article Cell biology Hematology

Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeletal dynamics in platelets

  • Text
  • PDF
Abstract

MASTL, a Ser/Thr kinase that inhibits PP2A-B55 complexes during mitosis, is mutated in autosomal dominant thrombocytopenia. However, the connections between the cell-cycle machinery and this human disease remain unexplored. We report here that, whereas Mastl ablation in megakaryocytes prevented proper maturation of these cells, mice carrying the thrombocytopenia-associated mutation developed thrombocytopenia as a consequence of aberrant activation and survival of platelets. Activation of mutant platelets was characterized by hyperstabilized pseudopods mimicking the effect of PP2A inhibition and actin polymerization defects. These aberrations were accompanied by abnormal hyperphosphorylation of multiple components of the actin cytoskeleton and were rescued both in vitro and in vivo by inhibiting upstream kinases such as PKA, PKC, or AMPK. These data reveal an unexpected role of Mastl in actin cytoskeletal dynamics in postmitotic cells and suggest that the thrombocytopenia-associated mutation in MASTL is a pathogenic dominant mutation that mimics decreased PP2A activity resulting in altered phosphorylation of cytoskeletal regulatory pathways.

Authors

Begoña Hurtado, Marianna Trakala, Pilar Ximénez-Embún, Aicha El Bakkali, David Partida, Belén Sanz-Castillo, Mónica Álvarez-Fernández, María Maroto, Ruth Sánchez-Martínez, Lola Martínez, Javier Muñoz, Pablo García de Frutos, Marcos Malumbres

×

Figure 5

Phosphoproteomic analysis in Mastl-mutant platelets.

Options: View larger image (or click on image) Download as PowerPoint
Phosphoproteomic analysis in Mastl-mutant platelets.
(A) Levels of p-MAP...
(A) Levels of p-MAPK/CDK substrates (proline-directed phosphosites) in resting platelets (0 min) or platelets activated with 0.05 IU/ml thrombin for 3, 7, and 15 minutes. A representative image from 2 separate experiments is shown. See complete unedited blots in the supplemental material. (B) Schematic representation of the protocol used in the phophoproteomics experiments. Pie chart represents the percentage of peptides phosphorylated in serine (pS), threonine (pT), or tyrosine (pY) over the total number of phosphopeptides detected. A pool of platelets from 3 mice per genotype was used for each time point. (C and D) FC (log2) of all identified phosphosites in Mastl(ED/ED) (C) or Mastl(Δ/Δ) (D) versus Mastl(+/+) platelets in resting conditions. Enrichment of specific Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in hyperphosphorylated (log2 FC ≥0.75) or hypophosphorylated (log2 FC ≤–0.75) sites was calculated using the mouse platelet proteome as a background. See Supplemental Tables 2 and 3 for a complete list of the enriched pathways. (E) Analysis of hyperphosphorylated motifs in Mastl(ED/ED) versus Mastl(+/+) resting platelets (left) or 3 minutes after activation with thrombin (right) using the de novo motif finder tool from the Posttranslational Modification Database (PHOSIDA).
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts